B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 8031-8040

  Boliar, Saikat ^a   Murphy, Megan K ^a   Tran, T Cameron ^a,b   Carnathan, Diane G ^a   Armstrong, Wendy S ^b   Silvestri, Guido ^a,b   Derdeyn, Cynthia A ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; FAS ANTIGEN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; KI 67 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4 LYMPHOCYTE COUNT; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MALE; MEMORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA; VIRION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; VIRAL LOAD; VIREMIA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864387150     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00771-12     Document Type: Article

References (54)

1. Ascher MS, Sheppard HW. 1988. AIDS as immune system activation: a model for pathogenesis. Clin. Exp. Immunol. 73:165-167.
2. Barber DL, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
3. Beirnaert E, et al. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14-24.
4. Beniguel L, et al. 2004. Specific antibody production by blood B cells is retained in late stage drug-naive HIV-infected Africans. Clin. Dev. Immunol. 11:121-127.
5. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
6. Blackburn SD, et al. 2009. Coregulation of CD8_ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29-37.
7. Day CL, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354.
8. De Milito A, et al. 2004. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103:2180-2186.
9. Doria-Rose NA, et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
10. Doria-Rose NA, et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199.
11. Dykhuizen M, et al. 1998. Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. J. Gen. Virol. 79(Pt 10): 2461-2467.
12. Euler Z, et al. 2012. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 86:2045-2055.
13. Euler Z, et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053.
14. Gray ES, et al. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4_T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
15. Hazenberg MD, et al. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17:1881-1888.
16. Huang KH, et al. 2010. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat. Commun. 1:102.
17. Kaufmann DE, et al. 2007. Upregulation of CTLA-4 by HIV-specific CD4_ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246-1254.
18. Kaufmann DE, Walker BD. 2009. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 182:5891-5897.
19. Kroon FP, van Dissel JT, de Jong JC, van Furth R. 1994. Antibody response to influenza, tetanus and pneumococcal vaccines in HIVseropositive individuals in relation to the number of CD4_lymphocytes. AIDS 8:469-476.
20. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. 2000. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18:3040-3049.
21. Lane HC, et al. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
22. Li B, et al. 2006. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80:5211-5218.
23. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
24. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
25. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18:567-576.
26. Lynch JB, et al. 2011. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J. Virol. 85:5252-5261.
27. Lynch RM, et al. 2011. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85:905-915.
28. Malaspina A, et al. 2006. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl. Acad. Sci. U. S. A. 103:2262-2267.
29. Mizuma H, Litwin S, Zolla-Pazner S. 1988. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin. Exp. Immunol. 71:410-416.
30. Moir S, et al. 2008. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205:1797-1805.
31. Moir S, et al. 2008. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J. Infect. Dis. 197:572-579.
32. Moir S, et al. 2001. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. U. S. A. 98:10362-10367.
33. Moir S, et al. 2004. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J. Exp. Med. 200:587-599.
34. Moore JP, et al. 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
35. Oballah P, et al. 2011. B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. PLoS One 6:e22653. doi:10.1371/journal.pone.0022653.
36. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. 1991. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin. Exp. Immunol. 84:185-189.
37. Piantadosi A, et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
38. Rainwater SM, et al. 2007. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr. HIV Res. 5:189-197.
39. Rodriguez-Barradas MC, et al. 1992. Antibody to capsular polysaccha-rides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis. 165:553-556.
40. Rong R, et al. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81:1350-1359.
41. Rong R, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594. doi:10.1371/journal.ppat.1000594.
42. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
43. Schmitz JE, et al. 2003. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77:2165-2173.
44. Schmitz JE, et al. 2009. Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. PLoS Pathog. 5:e1000691. doi:10.1371/ journal.ppat.1000691.
45. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
46. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. 1992. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J. Clin. Invest. 89:561-566.
47. Simek MD, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
48. Tasca S, et al. 2011. Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques. J. Virol. 85:3086-3094.
49. Titanji K, et al. 2010. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J. Clin. Invest. 120:3878-3890.
50. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. 2009. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23:2405-2414.
51. Watanabe N, et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4:670-679.
52. Zhang JY, et al. 2007. PD-1 up-regulation is correlated with HIV-specific memory CD8_ T-cell exhaustion in typical progressors but not in longterm nonprogressors. Blood 109:4671-4678.
53. Zhang Z, et al. 2011. B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J. Infect. Dis. 203:1668-1678.
54. Zhang ZQ, et al. 2007. Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 361:455-464.